| 51 |
24112719 | Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells. | 2013 Dec |
1 |
| 52 |
24263233 | Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. | 2013 Nov 22 |
1 |
| 53 |
22043997 | Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance. | 2012 Feb |
1 |
| 54 |
22238368 | MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. | 2012 Mar |
1 |
| 55 |
22293713 | Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. | 2012 May |
1 |
| 56 |
22407832 | Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. | 2012 May 1 |
2 |
| 57 |
22686613 | Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. | 2012 Jun 18 |
1 |
| 58 |
22745588 | Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. | 2012 May |
1 |
| 59 |
22815900 | Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. | 2012 |
1 |
| 60 |
22892392 | BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. | 2012 Sep 4 |
1 |
| 61 |
21252284 | Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. | 2011 Mar |
1 |
| 62 |
21385943 | Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. | 2011 Mar 22 |
1 |
| 63 |
21464044 | The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. | 2011 May 15 |
1 |
| 64 |
20103665 | Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. | 2010 Feb 1 |
1 |
| 65 |
20126311 | Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression. | 2010 Feb 2 |
1 |
| 66 |
20179222 | Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. | 2010 Mar 1 |
2 |
| 67 |
20457354 | Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts. | 2010 Jun 1 |
2 |
| 68 |
20501798 | Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. | 2010 Jun |
2 |
| 69 |
20511180 | ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. | 2010 Aug |
1 |
| 70 |
20855960 | Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. | 2010 Nov 1 |
1 |
| 71 |
19287975 | Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. | 2009 Apr |
1 |
| 72 |
18544666 | Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. | 2008 Sep |
1 |
| 73 |
18980964 | Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. | 2008 Nov 1 |
1 |
| 74 |
17308062 | Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. | 2007 Feb |
2 |
| 75 |
17513611 | Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. | 2007 May |
6 |
| 76 |
16397255 | Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. | 2006 Jan 1 |
1 |
| 77 |
16452222 | Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. | 2006 Feb 1 |
1 |
| 78 |
14737100 | Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. | 2004 Jan 22 |
2 |
| 79 |
14751502 | Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. | 2004 Feb 1 |
1 |
| 80 |
12214266 | Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. | 2002 Sep 12 |
5 |